Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab.

Shinoki T, Hara R, Kaneko U, Miyamae T, Imagawa T, Mori M, Yokota S.

Mod Rheumatol. 2012 Nov;22(6):871-6. doi: 10.1007/s10165-012-0595-z. Epub 2012 Feb 11.

PMID:
22322589
2.

Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis.

Yokota S, Miyamae T, Imagawa T, Katakura S, Kurosawa R, Mori M.

Clin Rev Allergy Immunol. 2005 Jun;28(3):231-8. Review.

PMID:
16129907
3.

Tocilizumab: a review of its use in the treatment of juvenile idiopathic arthritis.

Frampton JE.

Paediatr Drugs. 2013 Dec;15(6):515-31. doi: 10.1007/s40272-013-0053-1. Review.

PMID:
24155139
4.

IL-6 blockers in systemic onset juvenile idiopathic arthritis.

Barone P, Pignataro R, Garozzo MT, Leonardi S.

Immunotherapy. 2016;8(1):79-87. doi: 10.2217/imt.15.104. Epub 2015 Dec 7. Review.

PMID:
26642378
5.

Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review.

Chantarogh S, Vilaiyuk S, Tim-Aroon T, Worawichawong S.

BMC Nephrol. 2017 May 12;18(1):159. doi: 10.1186/s12882-017-0573-y. Review.

6.

Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.

Machado SH, Xavier RM.

Expert Opin Drug Saf. 2017 Apr;16(4):493-500. doi: 10.1080/14740338.2017.1303479. Review.

PMID:
28277841
7.

Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations.

Woerner A, von Scheven-GĂȘte A, Cimaz R, Hofer M.

Expert Rev Clin Immunol. 2015 May;11(5):575-88. doi: 10.1586/1744666X.2015.1032257. Epub 2015 Apr 4. Review.

PMID:
25843554
8.

Tocilizumab for the treatment of systemic juvenile idiopathic arthritis.

Herlin T.

Expert Rev Clin Immunol. 2012 Aug;8(6):517-25. Review.

PMID:
22992145
9.

Tocilizumab for the treatment of juvenile idiopathic arthritis.

Decelle K, Horton ER.

Ann Pharmacother. 2012 Jun;46(6):822-9. doi: 10.1345/aph.1Q756. Epub 2012 May 15. Review.

PMID:
22589451
10.

Influenza vaccination in children being treated with chemotherapy for cancer.

Goossen GM, Kremer LC, van de Wetering MD.

Cochrane Database Syst Rev. 2013 Aug 1;(8):CD006484. doi: 10.1002/14651858.CD006484.pub3. Review.

PMID:
23904194
11.

Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches.

Bruck N, Schnabel A, Hedrich CM.

Clin Immunol. 2015 Jul;159(1):72-83. doi: 10.1016/j.clim.2015.04.018. Epub 2015 May 6. Review.

PMID:
25956529
12.

Canakinumab for the treatment of systemic juvenile idiopathic arthritis.

Grom AA.

Expert Rev Clin Immunol. 2014 Nov;10(11):1427-35. doi: 10.1586/1744666X.2014.965149. Epub 2014 Oct 1. Review.

PMID:
25269376
13.

Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.

Orrock JE, Ilowite NT.

Expert Rev Clin Pharmacol. 2016 Aug;9(8):1015-24. doi: 10.1080/17512433.2016.1204910. Epub 2016 Jul 6. Review.

PMID:
27367267
14.

Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis.

Zhang X, Morcos PN, Saito T, Terao K.

Expert Rev Clin Pharmacol. 2013 Mar;6(2):123-37. doi: 10.1586/ecp.13.1. Review.

PMID:
23473591
15.

Guidance on using tocilizumab for juvenile idiopathic arthritis.

Yokota S, Imagawa T, Takei S, Murata T, Tomiita M, Itoh Y, Fujikawa S, Mori M.

Mod Rheumatol. 2011 Dec;21(6):563-71. doi: 10.1007/s10165-011-0464-1. Epub 2011 May 20. Review.

PMID:
21597951
16.

Tocilizumab - a novel therapy for non-organ-specific autoimmune diseases.

Kaly L, Rosner I.

Best Pract Res Clin Rheumatol. 2012 Feb;26(1):157-65. doi: 10.1016/j.berh.2012.01.001. Review.

PMID:
22424201
17.
18.

Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions.

Mellins ED, Macaubas C, Grom AA.

Nat Rev Rheumatol. 2011 Jun 7;7(7):416-26. doi: 10.1038/nrrheum.2011.68. Review.

19.

Tocilizumab in the treatment of systemic juvenile idiopathic arthritis.

Murakami M, Tomiita M, Nishimoto N.

Open Access Rheumatol. 2012 Jul 4;4:71-79. eCollection 2012. Review.

20.

Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition.

Grevich S, Shenoi S.

Adolesc Health Med Ther. 2017 Nov 9;8:125-135. doi: 10.2147/AHMT.S109495. eCollection 2017. Review.

Supplemental Content

Support Center